Clinical Trial Update: Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 pilot study evaluating the combination of paclitaxel and pembrolizumab in metastatic HER2-negative breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Breast - Female, Male Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-10-13